Chirag Shah, MD, on Assessing DCIS Recurrence Risk

December 10, 2020 By The ASCO Post Staff

Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study found that despite using traditional favorable-risk criteria, radiation recommendations were changed in more than 40% of patients (Abstract PS6-17).

Related Content